Drugs / TransCon TLR7/8 Agonist
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04799054 | Mar 2021 → Dec 2025 | head and neck squamous cell carcinoma, human papillomavirus-related squamous cell carcinoma, melanoma, metastatic neoplasm +1 | Ascendis Pharma A/S | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TransCon TLR7/8 Agonist | “TransCon™ TLR7/8 Agonist-an investigational sustained-release prodrug of resiquimod” PMID 36123697 ↗ Sep 2022 |
| Modality | Other / unclassified | “TransCon™ TLR7/8 Agonist-an investigational sustained-release prodrug of resiquimod” PMID 36123697 ↗ Sep 2022 |